Skip to main content
. 2009 Sep 24;5:757–766. doi: 10.2147/tcrm.s5189

Figure 3.

Figure 3

Efficacy of lacosamide (LCM) in partial epilepsy. Summary of the results of the phase III studies of LCM as add-on treatment of patients with partial seizures with or without secondary generalization – primary endpoint 2: responder rate, defined as reduction of at least 50% in seizure frequency from baseline to maintenance.

Notes: **P < 0.01 *P < 0.05